T. Rowe Price Associates’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $126M | Buy |
|
|||||
|
2025
Q2 | $64M | Buy |
|
|||||
|
2025
Q1 | $3.73M | Buy |
|
|||||
|
2024
Q4 | $2.64M | Buy |
|
|||||
|
2024
Q3 | $2.5M | Buy |
|
|||||
|
2024
Q2 | $2.19M | Buy |
|
|||||
|
2024
Q1 | $2.02M | Sell |
|
|||||
|
2023
Q4 | $11.7M | Buy |
|
|||||
|
2023
Q3 | $1.58M | Buy |
|
|||||
|
2023
Q2 | $1.47M | Buy |
|
|||||
|
2023
Q1 | $1M | Buy |
|
|||||
|
2022
Q4 | $1.12M | Buy |
|
|||||
|
2022
Q3 | $630K | Sell |
|
|||||
|
2022
Q2 | $560K | Buy |
|
|||||
|
2022
Q1 | $595K | Buy |
|
|||||
|
2021
Q4 | $390K | Sell |
|
|||||
|
2021
Q3 | $663K | Sell |
|
|||||
|
2021
Q2 | $50.5M | Buy |
|
|||||
|
2021
Q1 | $35.5M | Sell |
|
|||||
|
2020
Q4 | $84.7M | Sell |
|
|||||
|
2020
Q3 | $74.7M | Sell |
|
|||||
|
2020
Q2 | $89.3M | Buy |
|
|||||
|
2020
Q1 | $43.9M | Sell |
|
|||||
|
2019
Q4 | $166M | Buy |
|
|||||
|
2019
Q3 | $14.3M | Buy |
|
|||||
|
2019
Q2 | $14.9M | Buy |
|